Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

Phase 1 Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Brain Metastases

Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.

Inclusion Criteria:

• Refractory Brain Metastases
• At least 1 measurable intracranial lesion as defined by RECIST
• ECOG less than or equal to 1
• Adequate hematology/organ function
• No baseline peripheral or central neuropathy above grade 1

Exclusion Criteria:

• Hypersensitivity to Cremophor EL
• Pregnant or Lactating
• Spinal Cord Compression
• Pre-existing dementia/cognitive disfunction
• Require Neupogen or Neulasta to Maintain Neutrophil Count
• Have Primary Brain Cancer
• Have History of Ischemic Heart Disease
• Have Diabetes